This paper is in the following e-collection/theme issue:

Clinical Informatics (1022) Research Instruments, Questionnaires, and Tools (576)

Published on in Vol 22, No 2 (2020): February

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study

Authors of this article:

Tjalf Ziemssen1 Author Orcid Image ;   Daniela Piani-Meier2 Author Orcid Image ;   Bryan Bennett3 Author Orcid Image ;   Chloe Johnson3 Author Orcid Image ;   Katie Tinsley3 Author Orcid Image ;   Andrew Trigg3 Author Orcid Image ;   Thomas Hach2 Author Orcid Image ;   Frank Dahlke2 Author Orcid Image ;   Davorka Tomic2 Author Orcid Image ;   Chloe Tolley3 Author Orcid Image ;   Mark S Freedman4 Author Orcid Image
Article Authors Cited by (35) Tweetations (9) Metrics

Journals

  1. Inojosa H, Ziemssen T. How to reduce the delay of diagnosing secondary progression in multiple sclerosis. Multiple Sclerosis Journal 2021;27(4):646 View
  2. Inojosa H, Schriefer D, Ziemssen T. Clinical outcome measures in multiple sclerosis: A review. Autoimmunity Reviews 2020;19(5):102512 View
  3. Volkov A, Popova E. New tools for early detection of multiple sclerosis progression: MSProDiscuss questionnaire. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 2020;120(7):43 View
  4. Tolley C, Piani-Meier D, Bentley S, Bennett B, Jones E, Pike J, Dahlke F, Tomic D, Ziemssen T. A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm. JMIR Medical Informatics 2020;8(4):e17592 View
  5. Ziemssen T, Hoffmann O, Klotz L, Schreiber H, Weber M, Rauser B. Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA. JMIR Research Protocols 2020;9(7):e19598 View
  6. Inojosa H, Rauser B, Ettle B, Ziemssen T. The transitional phase of multiple sclerosis: The concept of PANGAEA 2.0 evolution study. Multiple Sclerosis and Related Disorders 2020;46:102523 View
  7. Ziemssen T, Kern R, Voigt I, Haase R. Data Collection in Multiple Sclerosis: The MSDS Approach. Frontiers in Neurology 2020;11 View
  8. Inojosa H, Proschmann U, Akgün K, Ziemssen T. Should We Use Clinical Tools to Identify Disease Progression?. Frontiers in Neurology 2021;11 View
  9. Scholz M, Haase R, Schriefer D, Voigt I, Ziemssen T. Electronic Health Interventions in the Case of Multiple Sclerosis: From Theory to Practice. Brain Sciences 2021;11(2):180 View
  10. Pratap A, Grant D, Vegesna A, Tummalacherla M, Cohan S, Deshpande C, Mangravite L, Omberg L. Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study. JMIR mHealth and uHealth 2020;8(10):e22108 View
  11. Boyko A, Therapontos C, Horakova D, Szilasiová J, Kalniņa J, Kolontareva J, Gross-Paju K, Selmaj K, Sereike I, Milo R, Gabelić T, Rot U. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals. Multiple Sclerosis and Related Disorders 2021;50:102778 View
  12. Kasatkin D, Khachanova N, Alifirova V, Boyko A, Bakhtiyarova K, Vlasov Y, Davydovskaya M, Evdoshenko E, Sivertseva S. New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis. Neurology, Neuropsychiatry, Psychosomatics 2021;13(1):138 View
  13. Alvarez E, Nair K, Gorritz M, Bartolome L, Maloney H, Ding Y, Golan T, Wade R, Kumar R, Su W, Shah R, Russo P. Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey. Multiple Sclerosis and Related Disorders 2021;50:102858 View
  14. Hoffmann O, Gold R. Krankheitsmodifizierende Therapie der sekundär progredienten Multiplen Sklerose. Der Nervenarzt 2021;92(10):1052 View
  15. Inojosa H, Akgün K, Haacke K, Ziemssen T. MSProDiscuss – Entwicklung eines digitalen Tools zur standardisierten Patientenanamnese, um Progredienz bei Multipler Sklerose zu identifizieren. Fortschritte der Neurologie · Psychiatrie 2021;89(07/08):374 View
  16. Voigt I, Inojosa H, Dillenseger A, Haase R, Akgün K, Ziemssen T. Digital Twins for Multiple Sclerosis. Frontiers in Immunology 2021;12 View
  17. De Angelis M, Lavorgna L, Carotenuto A, Petruzzo M, Lanzillo R, Brescia Morra V, Moccia M. Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review. Journal of Clinical Medicine 2021;10(11):2328 View
  18. Ziemssen T, Giovannoni G, Alvarez E, Bhan V, Hersh C, Hoffmann O, Oreja-Guevara C, Robles-Cedeño R, Trojano M, Vermersch P, Dobay P, Khwaja M, Stadler B, Rauser B, Hach T, Piani-Meier D, Burton J. Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. Journal of Medical Internet Research 2021;23(10):e29558 View
  19. Trentzsch K, Schumann P, Śliwiński G, Bartscht P, Haase R, Schriefer D, Zink A, Heinke A, Jochim T, Malberg H, Ziemssen T. Using Machine Learning Algorithms for Identifying Gait Parameters Suitable to Evaluate Subtle Changes in Gait in People with Multiple Sclerosis. Brain Sciences 2021;11(8):1049 View
  20. Lewis S, Wray S, Evans E, Romano C, Bartolome L, Su W, Shah R, Russo P. Patients’ Experiences in Transitioning to Secondary Progressive Multiple Sclerosis: Qualitative Interviews. Neurology and Therapy 2021;10(2):887 View
  21. Voigt I, Ziemssen T. Daten sammeln aus der Praxis: der Weg zum digitalen MS-Zwilling. DNP - Der Neurologe & Psychiater 2021;22(6):30 View
  22. Ziemssen T, Bhan V, Chataway J, Chitnis T, Campbell Cree B, Havrdova E, Kappos L, Labauge P, Miller A, Nakahara J, Oreja-Guevara C, Palace J, Singer B, Trojano M, Patil A, Rauser B, Hach T. Secondary Progressive Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation 2023;10(1) View
  23. Lus G, Bassano M, Brescia Morra V, Bonavita S, Gallo A, Maimone D, Malerba L, Maniscalco G, Saccà F, Salemi G, Turrini R, Cottone S, Sessa E, Buccafusca M, Grimaldi L. Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals’ perspective. Neurological Sciences 2023;44(1):45 View
  24. Ziemssen T, Vandercappellen J, Jordan Mondragon V, Giovannoni G. MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression. Journal of Clinical Medicine 2022;11(15):4401 View
  25. Heibel M, Groth M, Beier S, Knapek S, Hemstedt T. Versorgungsrealität von Patienten mit sekundär-progredienter Multipler Sklerose in Deutschland. Nervenheilkunde 2022;41(04):262 View
  26. Thompson C, Pulido M, Babu S, Zenzola N, Chiu C. Communication between persons with multiple sclerosis and their health care providers: A scoping review. Patient Education and Counseling 2022;105(12):3341 View
  27. Hamdy E, Talaat F, Ramadan I, Marouf H, Hamdy M, Sadallah H, El-Ashmawy G, Elsalamawy D, Said S. Diagnosing ‘transition’ to secondary progressive multiple sclerosis (SPMS): A step-by-step approach for clinicians. Multiple Sclerosis and Related Disorders 2022;60:103718 View
  28. Klinsing S, Yalachkov Y, Foerch C. Difficulty in identification of patients with active secondary progressive multiple sclerosis by clinical classification tools. European Journal of Neurology 2022;29(4):1100 View
  29. Giovannoni G, Alvarez E, Tutton E, Hoffmann O, Xu Y, Vermersch P, Oreja-Guevara C, Trojano M, Gold R, Robles-Cedeño R, Khwaja M, Stadler B, Vandercappellen J, Ziemssen T. Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis. DIGITAL HEALTH 2023;9 View
  30. Matrosova M, Belskaya G, Bryukhov V, Popova E, Krotenkova M. Clinical markers for unfavorable course of multiple sclerosis. Annals of Clinical and Experimental Neurology 2023;17(3):41 View
  31. Nowak-Kiczmer M, Niedziela N, Czuba Z, Sowa P, Wierzbicki K, Lubczyński M, Adamczyk-Sowa M. A comparison of serum inflammatory parameters in progressive forms of multiple sclerosis. Multiple Sclerosis and Related Disorders 2023;79:105004 View
  32. Gakis G, Angelopoulos I, Panagoulias I, Mouzaki A. Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation. Autoimmunity Reviews 2024;23(2):103480 View
  33. Deri N, Barboza A, Vrech C, Rey R, Burgos M, Fiol M, CalvoVildoso C, Patrucco L, Jose G, Aliberti P, Chirico D, Federico M, Seifer G, Piedrabuena R. Clinical characterization of long-term multiple sclerosis (COLuMbus) patients in Argentina: A cross-sectional non-interventional study. Multiple Sclerosis and Related Disorders 2024;83:105421 View
  34. Brahma A, Chatterjee S, Seal K, Fitzpatrick B, Tao Y. Development of a Cohort Analytics Tool for Monitoring Progression Patterns in Cardiovascular Diseases: Advanced Stochastic Modeling Approach. JMIR Medical Informatics 2024;12:e59392 View
  35. Meca-Lallana J, Robles R, Landete L, Téllez N, García-Domínguez J, Garcés P, Costa-Frossard L. A Clinical Care Algorithm for Detecting Progression in Multiple Sclerosis: RetratEMos Project. Cureus 2024 View